Androgen receptor-positive ductal adenocarcinoma of the nasolacrimal duct: A case report

Abstract

PurposePrimary ductal adenocarcinoma arising in the structures of the lacrimal apparatus is extremely rare, and the entity is considered a lacrimal counterpart of salivary duct carcinoma, of which the majority are known to express androgen receptor (AR). Less than 10 cases of AR-positive carcinomas of lacrimal gland or lacrimal sac have been described.ObservationsWe present a primary ductal adenocarcinoma with AR expression involving the nasolacrimal duct of a middle-aged patient who had suffered from right eyelid swelling, diplopia and epiphora for 4 months. Although the tumor histologically resembled oncocytic carcinoma, electron microscopic examination did not show cytoplasmic accumulation of mitochondria, which excluded the diagnosis of oncocytic carcinoma with AR positivity.Conclusions and importanceWe concluded that this is the first case of AR-positive ductal adenocarcinoma arising from nasolacrimal duct. It is possible that some of the previously documented oncocytic carcinomas of the lacrimal drainage system may include ductal adenocarcinomas with oncocytic features.

Assessment of Immunohistochemical Expression of Androgen Receptor and its Correlation with Histopathological Prognostic Factors in Prostatic Carcinoma

“…Androgens regulate the proliferation rates of epithelial cells, so increased androgen levels or AR activity could result in unlimited proliferation and cancer development. AR is required for normal prostate function and is expressed in prostatic intra-epithelial neoplasias (PIN) and early carcinoma; however, it is also expressed in advanced and metastatic carcinoma (18) . We performed a cross-section analytical study at the pathology department of the Faculty of Medicine at Suez Canal University.…”

Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report

“…Two corneal lesions were reported as ocular adverse effects of T-DM1 administration [5, 6] based on the expression of HER2 in corneal epithelial cells and its susceptibility to trastuzumab harboring agents. In literature, two studies have reported HER2 overexpression in adenocarcinoma of lacrimal sac and nasolacrimal duct [11, 12], but not in normal nasolacrimal epithelium. If HER2 is also expressed in the normal nasolacrimal epithelium, nasolacrimal stenosis in our case can be explained in part as an effect of trastuzumab.…”